



US006093745A

United States Patent [19]**Hammes et al.**[11] **Patent Number:** **6,093,745**[45] **Date of Patent:** **Jul. 25, 2000**[54] **METHODS AND COMPOSITION FOR
TREATING SKIN PROLIFERATIVE
DISEASES**[75] Inventors: **Hans-Peter Hammes**, Linden,
Germany; **Michael Brownlee**, New
York, N.Y.[73] Assignee: **PsoRx, L.L.C.**, Palo Alto, Calif.[21] Appl. No.: **08/978,035**[22] Filed: **Nov. 25, 1997**[51] **Int. Cl.⁷** **A61K 31/155**[52] **U.S. Cl.** **514/634**[58] **Field of Search** 514/634[56] **References Cited****U.S. PATENT DOCUMENTS**

4,006,249	2/1977	Porter et al. .	
4,201,788	5/1980	Voorhees et al. .	
4,618,344	10/1986	Wells	8/161
5,449,688	9/1995	Wahl et al. .	
5,501,849	3/1996	Lee .	
5,534,551	7/1996	Page et al.	514/634
5,607,679	3/1997	Rhodes .	

FOREIGN PATENT DOCUMENTS

WO 96/12483 5/1996 WIPO .

OTHER PUBLICATIONSErdman et al., (1989) *Gastroenterology*, 96:1533–1538.
Heck et al., (1992) *Journal of Biological Chemistry*
267:21277–21280.Misko et al. (1993) *European Journal of Pharmacology*,
233:119–125.Kolb–Bachofen et al. (1994) *Lancet*, 344:139.Morhenn, Vera B. (1997) *Immunology Today*, 18:433–436.Rokkas et al., (1990) *Digestion* 46:447–457.Saeki et al. (1975) *The Journal of Pharmacology and
experimental Therapeutics*, 193:910–917.Sirsjö et al. (1996) *British Journal of Dermatology*,
134:643–648.Sugiyama et al., (1993) *Toxicology Letters*, 69:273–278.*Primary Examiner*—James H. Reamer[57] **ABSTRACT**

Methods and a compositions are provided for treating a skin proliferation disease such as psoriasis to inhibit the proliferation of epidermal cells, particularly keratinocytes and to reduce the symptoms of erythematous scales associated with the disease. The method comprises administering to a mammalian host with a skin proliferation disease a composition comprising an effective amount of an aminoguanidine composition, generally in a pharmaceutically acceptable carrier. The invention also provides a composition comprising an aminoguanidine composition which can be formulated in a pharmaceutically acceptable carrier, in a topical application form or for oral administration. The composition finds use in alleviating symptoms associated with the disease, such as reducing size, thickness or scales of a psoriatic lesion, reducing erythema, decreasing itching and decreasing induration.

6 Claims, 3 Drawing Sheets**(3 of 3 Drawing Sheet(s) Filed in Color)**